Zacks Small-Cap Research

November 25, 2013
Grant Zeng, CFA
312-265-9466
gzeng@zacks.com

scr.zacks.com
111 North Canal Street, Chicago, IL 60606

Advaxis Inc. (ADXS-NASDAQ)

ADXS: Balance sheet boosted dramatically by new financing, on track to advance its pipeline with focus on ADXS-HPV cervical cancer, -- Outperform

Current Recommendation	**Outperform**
Prior Recommendation	Neutral
Date of Last Change	11/06/2013
Current Price (11/22/13)	$3.50
12-month Target Price	**$7.50**

OUTLOOK

Advaxis is a Listeria based immunotherapy company focused on the development of immunotherapeutics for cancer treatment. We are optimistic about the Company's unique Listeria platform technology which has advantages over its peers. The Company's lead drug candidate ADXS-HPV is in Phase II clinical trials for the treatment of cervical cancer and cervical dysplasia. Two more Phase I/II trials are initiated for the treatment of head and neck cancer and anal cancer. Other pipeline candidates target breast, brain and prostate cancer.

We rate its shares Outperform.

SUMMARY DATA

52-Week High	**$17.38**
52-Week Low	**$2.70**
One-Year Return (%)	**-29.90**
Beta	**1.11**
Average Daily Volume (sh)	**278,590**
Shares Outstanding (mil)	**11.5**
Market Capitalization ($mil)	**$38**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**1**
Insider Ownership (%)	**13.4**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2011 Estimate	**N/A**
P/E using 2012 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**Above Avg.,**
Type of Stock	**N/A**
Industry	**Med Products**
Zacks Rank in Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Jan)	Q2 (Apr)	Q3 (Jul)	Q4 (Oct)	Year (Oct)
2012	0.00 A	0.09 A	0.18 A	0.24 A	0.51A
2013	0.00 A	0.00 A	0.00 A	0.00 E	0.00 E
2014					2.00 E
2015					9.50 E

Earnings per Share
(EPS is operating earnings before non recurring items)

	Q1 (Jan)	Q2 (Apr)	Q3 (Jul)	Q4 (Oct)	Year (Oct)
2012	-$1.87 A	-$1.13 A	-$1.12 A	-$1.03 A	-$5.00 A
2013	-$0.52 A	-$1.29 A	-$0.37 A	-$0.43 E	-$2.34 E
2014					-$1.23 E
2015					-$0.75 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

© Copyright 2013, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

- **Balance sheet boosted by recent financing;**
- **Updated Phase II Results for ADXS-HPV at SITC;**
- **Two Phase I/II trials of ADXS-HPV for head and neck cancer initiated;**
- **Reported encouraging preliminary Phase I data of ADXS-cHER2 for Canine Osteosarcoma;**
- **Multiple short term catalysts including advancing lead product candidate, ADXS-HPV, toward a registration development program;**
- **Will continue to strengthen financial position;**
- **Valuation is attractive.**

Balance Sheet Boosted by Recent Financing

On October 22, Advaxis announced the closing of its public offering of 6,612,500 shares of common stock, and warrants to purchase up to an aggregate of 3,306,250 shares of its common stock, including 862,500 shares and warrants to purchase 431,250 shares that were offered and sold by Advaxis, Inc. pursuant to the full exercise of the underwriters' over-allotment option, at a price to the public of $4.00 per share and $0.001 per warrant. The warrants have a per share exercise price of $5.00, 125% of the public offering price of the common stock, are exercisable immediately, and expire five years from the date of issuance. Total gross proceeds from the offering were approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.

This financing after the 1-for-125 reverse stock split is a great achievement for Advaxis. It not only boosts the company's balance sheet dramatically, but also validates the company's cancer vaccine technology and clinical programs.

Current cash could last through 2Q15 according to our financial model. With boosted balance sheet, Advaxis should be able to focus on advancing its promising lead drug candidate ADXS-HPV.


Updated ADXS-HPV Cervical Cancer Phase II Results for ADXS-HPV at SITC

On November 9, Advaxis announced final updated 18-month survival data from **Phase II** ADXS-HPV (Lm-LLO-E7-15) study evaluating the safety and efficacy of ADXS-HPV ($1x10^9$ cfu) with and without cisplatin (40 mg/m^2, weekly x5) in 110 patients with **recurrent cervical cancer** in two treatment arms of 55 patients each. The primary endpoint of the study is overall survival. These data were presented at the 2013 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD, on November 9, 2013 (Poster #258).

As a reminder, ADXS initiated the **Phase II** study in November 2010 in India in 110 Patients with recurrent or refractory cervical cancer. This study is being conducted at 22 sites in India. All patients randomized to the trial have been previously treated with chemotherapy, radiotherapy or both, and their cancer has progressed subsequent to treatment and has been confirmed by CT or radiologic scan.

Patients are randomized into 2 groups of 55 patients receiving: ADXS-HPV or ADXS-HPV + cisplatin (40 mg/m^2, weekly x5). Patients got either 3 doses of ADXS-HPV at 1×10^9 CFU or 4 doses of ADXS-HPV at 1×10^9 CFU with **cisplatin** chemotherapy. Naprosyn and oral promethazine are given as premedications and a course of ampicillin is given 72h after infusion thereby clearing any residual vector. Patients

receive CT scans at baseline and Days 84, 184, 273, 365 and 545. **The primary endpoint is 12 month survival**.



Enrollment was completed in May 2012 and results were presented at multiple scientific meetings.

The last patient last visit (Day 545) occurred on October 18, 2013. The final 18-month survival data are 28% (31/110) which is updated from the preliminary18-month survival of 22% (16/73) reported at the 2013 ASCO Annual Meeting on June 2, 2013. The final 12-month survival was 36% (39/110). These data are comparable to the results for the landmark 2004 Moore Phase III study conducted by the Gynecologic Oncology Group of cisplatin alone and cisplatin plus paclitaxel in recurrent cervical cancer patients with the same initial performance (health) status (0-2). In that study, 12 month survival was presented as 35% for cisplatin alone and 32% for the combination and 18 month survival was presented as 20% for combination therapy and 12% for cisplatin, alone.

Patients*	Overall (N=110)	ADXS-HPV ALONE (N=56)	ADXS-HPV + CISPLATIN (N=54)
9 Months (final)			
% alive (#)	46% (51/110)	43% (24/56)	50% (27/54)
12 Months (final)			
% alive (#)	36% (39/110)	32% (18/56)	39 % (21/54)
18 Months (ongoing)			
% alive (#)	28% (31/110)	25% (14/56)	31% (17/54)


Median overall survival in the Advaxis study was approximately 8.5 months which is indicative of the late stage of disease and baseline performance status of the patients. Those patients that completed the study will continue to be followed for survival. Survival results were not significantly different between treatment groups with or without cisplatin chemotherapy or who had previous therapy comprised of a combination of chemotherapy and radiation, radiation alone, or chemotherapy alone.

The tumor response rate was 11% with 6 complete responses and 6 partial responses/110 patients and was similar in both treatment groups per RECIST 1.1 criteria. Stable disease >3 months was observed in 35 additional patients, for a disease control rate of 43% (47/110). Average duration of response after 12

month minimum follow-up was 10.5 months for both treatment groups. In those patients treated with ADXS-HPV alone who had stable disease, the average duration of response was 6 months compared to 4.1 months in patients treated with ADXS-HPV plus cisplatin. Activity was observed against all high risk HPV strains detected, including 16, 18, 31, 33, and 45.

Subset analyses showed that the combination arm (addition of cisplatin to ADXS-HPV) did not significantly improve survival or tumor response; and survival and tumor response were equally strong in patients with aggressive disease (defined as recurrence ≤2 years from initial diagnosis) versus non-aggressive disease (defined as recurrence >2 years from initial diagnosis).

The tolerability of ADXS-HPV continues to compare favorably with single agent and combination chemotherapies active in this disease setting. 110 patients received 264 doses of ADXS-HPV at $1x10^9$ cfu per dose. 42% (46/110) of patients experienced 104 mild-moderate Grade 1-2 adverse events and 2% (2/110) of patients experienced a serious adverse event (1 Grade 3 and 1 Grade 4) related/possibly related to ADXS-HPV. This compares to published serious adverse event rates of 100%-400% related to treatment in studies on a range of chemotherapy regimens for cervical cancer.



Advaxis also presented data on initial biomarker analysis of a subset of serum samples collected from patients in Lm-LLO-E7-15, pre- and post-dosing with ADXS-HPV. Administration of ADXS-HPV immunotherapy resulted in increased expression of cytokines (IL6, IL-8, IL10, INF-γ and TNF-α) and chemokines (MIP-1α, MIP-1β and MCP-1) indicating activation of innate immunity. An association was also found between changes in the expression of cytokine and/or other serum factors and the severity of adverse events. These data may provide future screening tools to assist in predicting clinical efficacy and to monitor and manage side effects.

Relative Increase In Cytokines And Chemokines Post-Dose

Cytokine/ Chemokines	Relative Fold Increase (2h)	Relative Fold Increase (4h)
IL-6	34.00	32.68
IL-8	22.50	12.80
IL-10	28.47	33.78
IL-18	0.57	0.63
MIP-1 α	3.00	2.10
INF-γ	2.10	1.80
MCP-1	35.52	23.94
TNF-α	19.21	11.78
TNF-R2	1.94	1.84

Figure 2. *Serum samples analyzed thus far using ELISA shows relative increase in cytokines and chemokines at 2 and 4 hours post dosing. More than a 15-fold increase is observed in the level of cytokines (IL-6, IL-8, IL-10 and TNF-α) and chemokine (MCP-1) post-administration of ADXS11-001, indicating strong stimulation of innate immunity.*

Next Step: Advaxis plans to conduct end of Phase II meeting with FDA soon. The company is preparing the Phase III protocols and will submit a SPA to the FDA. Two Phase III trials will be conducted.

Our Takeaways from the Updated Results

The data presented at the SITC are very encouraging.

After 110 patients and 264 doses, the safety data is encouraging. ADXS-HPV continues to demonstrate a well-tolerated and manageable safety profile with 42% of patients reporting Grade 1 or 2 transient, flu-like symptoms that self-resolve or respond to symptomatic treatment. Less than 2% of patients reported serious adverse events associated with ADXS-HPV. Published studies on chemotherapy treated patients like these show 100% of patients experiencing severe adverse events, usually multiple times.

Great efficacy has been observed which are very promising. Compared to GOG historical one year survival of 5%, ADXS-HPV has achieved 36% one year survival rate. This is a huge improvement. Other literature data showed that generally, recurrent cervical cancer has a poor 1-year survival rate of 15% and a 5-year survival rate of 3-13%. ADXS-HPV's 36% one year survival rate is also a 100% improvement. 18 month survival also reached 28%. Further investigation is warranted.

ADXS-HPV appears to be emerging as an active agent in recurrent/refractory cervical cancer with significantly less toxicity than chemotherapy.

The positive ADXS-HPV data may trigger partnership talks for Advaxis in our view.

ADXS-HPV for cervical cancer is the Company's current focus. Advaxis plans to conduct new short term clinical trials to support its partnership talks as well as the planned Phase III trial of ADXS-HPV.

Two Phase I/II Trial of ADXS-HPV Initiated for Head and Neck Cancer

On May 8, 2012, Advaxis' partner Cancer Research UK (CRUK) began to enroll patients into **REALISTIC**, a **Phase I/II study** to investigate the use of ADXS-HPV for the treatment of **27 patients** with HPV positive head and neck cancer. HPV is associated with 40-70% of head and neck cancers.

This trial is being conducted at the Aintree Hospital at the University of Liverpool, the Royal Marsden Hospital at the University of London, and the Cardiff Hospital at the University of Wales. The study will investigate the safety and efficacy of ADXS-HPV in **preventing recurrence** of head and neck cancer among patients who have been treated with surgery, radiotherapy, and/or chemotherapy; alone or in combination. A maximum of 45 patients are to be enrolled in this study, and all costs will be assumed by CRUK.

Due to regulations in the UK, the first patient was dosed on October 23, 2013.

On November 20, 2013, Advaxis announced that the Icahn School of Medicine at Mount Sinai (ISMMS) will initiate a **Phase I/II** study of ADXS-HPV in **25 patients** with HPV-positive head and neck cancer.

This clinical trial will be the **first study** to evaluate the effects of ADXS-HPV in patients when they are **newly diagnosed with HPV-associated head and neck cancer**, prior to receiving any chemotherapy or radiation. This study will be an important first step toward understanding ADXS-HPV's potential to treat this type of cancer before chemotherapy and/or radiation and its potential to reduce the need for these treatments.

This non-randomized investigator-initiated study has been designed to evaluate the safety and immunogenicity of ADXS-HPV in patients with HPV-positive stage II-IV squamous cell carcinoma of the oropharynx (OPCSC). In this study, 15 patients will receive ADXS-HPV treatment followed by ablative transoral robotic surgery (TORS), and 10 patients will serve as the control group and receive only TORS. TORS is FDA-approved for head and neck cancer and is considered to be the standard of care therapy for OPCSC in appropriate patients.

These two trials further expands the ADXS-HPV clinical development program to another HPV-associated tumor type.

According to the National Cancer Institute and the American Cancer Society, head and neck cancers represent approximately 3 percent of all cancers in the United States and are twice as common in men as in women. Historically, head and neck cancer has been associated with people over the age of 50 and with the use of alcohol and tobacco (including smokeless tobacco), however, there has been a recent rise in HPV-related oropharyngeal cancers in caucasian men under the age of 50. Recurrence rates in patients are high, in some studies over 80% within 2 years. ADXS-HPV may provide a treatment option for doctors and patients with HPV-related head and neck cancers.

ADXS-HPV is granted orphan drug designation for treatment of HPV-associated head and neck cancer in the US.

Encouraging Interim Phase I Data of ADXS-cHER2 For Canine Osteosarcoma

On July 17, Advaxis announced updated preliminary data from a dose escalation **Phase I study** evaluating the safety and efficacy of ADXS-cHER2 in the treatment of dogs with **osteosarcoma** that overexpress human epidermal growth factor receptor-2 (HER2).

ADXS-cHER2 is an Lm-LLO immunotherapy for HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and for osteosarcoma in canines). ADXS-cHER2 secrets the cHER2 antigen, fused to LLO, directly inside APC that are capable of driving a cellular immune response to cHER2 overexpressing cells.

As a reminder, on August 2, 2012, Advaxis announced the initiation of a **Phase I study** of ADXS-HER2 for canine osteosarcoma at the University of Pennsylvania, School of Veterinary Medicine. In this trial, dogs that have undergone standard of care treatment for osteosarcoma, including limb amputation and follow up chemotherapy, and that over-express the tumor marker HER-2/neu in their tumors, are treated

with Advaxis agent ADXS-cHER2. This immunotherapy is designed to stimulate the dog's immune system to attack cancer cells that express the HER-2/neu marker. The goal is to elicit anti-tumor immunity and prolong survival.

Updated preliminary data from the first two of three dose groups (6 dogs/3 dogs per dose group) show a significant survival advantage for dogs that received standard of care (SOC) plus ADXS-cHER2 compared to 11 dogs whose owners elected not to participate in the trial but who were followed for survival (p=0.04). At this point in the study, 8 of 9 dogs treated with ADXS-cHER2 are alive (mean survival undefined), compared with 5 of 11 dogs in the control group (mean survival 265 days).

ADXS-cHER2 continues to be well-tolerated with the dogs experiencing only mild, easily managed side effects (fever, increased heart rate, and vomiting) consistent with immune activation (cytokine release syndrome) observed at the time of treatment. There is no evidence of any cumulative or long-term side effects on the dogs, including their cardiovascular systems.

Once the dose has been selected, the study is intended to expand into **Phase II** and additional collaborative academic centers will be added.

Canine osteosarcoma is a leading killer of large breed dogs that causes tumors to form on long leg bones. Dogs undergoing standard of care (SOC) treatment (affected limb amputation and follow-up chemotherapy) have a median survival rate of only 1 year. We believe there is a significant commercial opportunity for ADXS-cHER2 in the veterinary medical market. Advaxis is discussing these data with animal health divisions of several major pharmaceutical companies.

Pipeline further Expanded by New Phase I/II Trial Of ADXS-HPV in Anal Cancer

On Feb 19, 2013, Advaxis announced that the Brown University Oncology Research Group (BrUOG) will be coordinating a **Phase I/II study** of ADXS-HPV in 25 patients with HPV-associated **anal cancer**. Dr. Howard Safran, professor of medicine, will be principal investigator. Patients will be treated at Rhode Island Hospital and The Miriam Hospital (the main teaching hospitals of The Warren Alpert Medical School of Brown University). Multiple institutions will collaborate.

This non-randomized, open-label, multi-center study will evaluate the safety and effectiveness of ADXS-HPV when combined with standard chemotherapy and radiation treatment for anal cancer. The primary objectives of the trial include the evaluation of adverse events and the evaluation of 6-month clinical response.

As of July 2013, 3 patients have been enrolled in the study. Multiple institutions will collaborate.

Virtually all cases of squamous cell cancer (SCC) of the anus are caused by a Human Papilloma Virus (HPV) infection. Anal cancer cells infected with HPV have the tumor associated antigen HPV E7. ADXS-HPV causes antigen presenting cells to stimulate other immune cells to attack cancer expressing HPV E7. In Phase I clinical trials and preliminary data from ongoing Phase II trials, ADXS-HPV has been safely administered to 193 patients with other HPV-associated diseases (recurrent/refractory cervical cancer and CIN 2/3), and has demonstrated clinical benefit as a single agent or in combination with chemotherapy.


This new indication of ADVX-HPV for anal cancer is an important step for the pipeline expansion. With this new indication, ADXS has now a series of clinical trials under study. This is quite unusual to a small cap biotech company.

ADXS-HPV Combination Study Significantly Improves Therapeutic Efficacy in Preclinical Study

On September 5, Advaxis announced the publication of preclinical research with ADXS-HPV in combination with PD-1 antibody for the treatment of HPV-associated cancers.

The studies demonstrated that treatment with ADXS-HPV immunotherapy, in combination with an anti-PD-1 antibody, significantly improved immune and therapeutic efficacy in **preclinical mouse models**. In addition, the study showed that a significant reduction of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC) in both the spleen and the tumor microenvironment were mediated solely by the ADXS-HPV immunotherapy. The addition of anti-PD-1 antibody to the immunotherapy treatment resulted in a significant increase in antigen-specific immune responses in the periphery and in CD8 T cell infiltration into the tumor. As a result, this treatment combination led to significant inhibition of tumor growth and prolonged survival/complete regression of tumors in treated animals.

Given the findings in the mouse model, additional studies were conducted to evaluate activity in human cells. In separate studies, ADXS-HPV immunotherapy treatment was found to significantly up-regulate surface PD-L1 expression on human monocyte-derived dendritic cells isolated from healthy volunteers. This finding suggests that the combination of ADXS-HPV immunotherapy with an anti-PD-1 antibody could have clinical application.




1. This study is being conducted by the Gynecologic Oncology Group

Huge Market Potential For ADXS-HPV

Cervical cancer is a worldwide problem and ranks as the 2nd leading cause of cancer death of women in the world. According to WHO, about 630 million people are infected with one of the over 100 strains of HPV. Global prevalence of clinically pre-malignant HPV infections is between 28 to 40 million women. Approximately 500,000 women are diagnosed of cervical cancer each year and about 11.4% of women in the general population are estimated to harbor cervical HPV infection. In the US, about 12000 new cases of cervical cancer are diagnosed each year. Prevalence of cervical cancer is higher in developing countries and India, China and South America are the three regions with highest cervical cancer prevalence (50% of cervical cancer burden).

In addition to cervical cancer, ADXS-HPV has potential to target other HPV-mediated cancers, which further expand ADXS-HPV's market. The Company already initiated clinical studies of ADXS-HPV for head & neck cancer as well as anal cancer.



Valuation Is Attractive

We maintain our Outperform rating for ADXS and reiterate our 12-month price target of $7.50 per share.

We think Advaxis' live, attenuated Listeria technology is a unique immunotherapeutic platform which can target various cancer indications and infectious diseases. This technology has advantages over other immunotherapies in three unique ways:

- Advaxis' Listeria-based cancer vaccine can deliver bioengineered cancer antigen fused with a unique, proprietary strong adjuvant LLO which elicits both innate and adaptive immune systems in the body to fight cancer. The immune response elicited by Advaxis' cancer vaccines has been the most comprehensive and robust so far in the industry.

- Advaxis' cancer vaccines can reduce the amount of regulatory T cells and myeloid suppressor cells which help protect tumors from attacking by cytotoxic T cells.

- Another distinctive feature of Advaxis' cancer vaccines is its ability to change the ratio between killer T-cells and regulatory T cells (the Kill Ratio) inside the tumor from a 1:1.3 to a 22.7:1.

Based on this unique platform technology, Advaxis has established a pipeline targeting a variety of cancer indications including cervical cancer/cervical dysplasia, head and neck cancer, prostate cancer, anal cancer and breast/brain cancers.

In terms of valuation, we think Advaxis is undervalued. The Company should be worth more than current value of $38 million in market cap in our view.

Currently, the Company shares are trading at about $3.40 per share which values the Company at about $38 million in market cap based on 11.5 million outstanding shares. This is certainly a deep discount.

We also reminder investors that the Company recently completed a $26.5 million financing, which boosted the balance sheet greatly. Further, according to management, partnership talks continue with big pharma companies about its cervical cancer program. With the preliminary positive Phase II data of ADXS-HPV for cervical cancer, partnership may be able to materialize in 2014.

Our price target of $7.50 per share values the Company at $86 million in market cap, which is still conservative. Apparently, risk is also high for Advaxis at this stage. We will keep a close eye on cash balance.


PROJECTED INCOME STATEMENT

	2012A (Oct)					2013E (Oct)					2014E (Oct)	2015E (Oct)
$ in million except per share data	Q1A	Q2A	Q3A	Q4A	FYA	Q1A	Q2A	Q3A	Q4E	FYE	FYE	FYE
Product Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$5.00
R&D revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.00	$4.50
Total Revenues	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$2.00**	**$9.50**
YOY Growth	-	-	-	-	-	-	-	-	-	-	-	*475.0%*
CoGS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Income	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$2.00**	**$9.50**
Gross Margin	-	-	-	-	-	-	-	-	-	-	*100.0%*	*100.0%*
R&D	$2.21	$2.22	$2.25	($0.03)	$6.65	$0.98	$2.11	$1.32	$3.00	$7.41	$12.00	$15.00
% R&D	-	-	-	-	-	-	-	-	-	-	-	-
SG&A	$1.03	$1.01	$1.33	$2.31	$5.69	$1.20	$3.36	$1.73	$1.75	$8.05	$7.50	$8.50
% SG&A	-	-	-	-	-	-	-	-	-	-	-	-
Other	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Other	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	**($3.2)**	**($3.2)**	**($3.6)**	**($2.3)**	**($12.3)**	**($2.2)**	**($5.5)**	**($3.1)**	**($4.8)**	**($15.5)**	**($17.5)**	**($14.0)**
Operating Margin	-	-	-	-	-	-	-	-	-	-	-	-
Other Net	($1.0)	$0.6	$0.5	($0.2)	($0.1)	($4.4)	$0.0	$1.3	($0.2)	($3.3)	($1.0)	($1.0)
Pre-Tax Income	**($4.3)**	**($2.6)**	**($3.1)**	**($2.4)**	**($12.4)**	**($6.6)**	**($5.5)**	**($1.8)**	**($5.0)**	**($18.8)**	**($18.5)**	**($15.0)**
Income taxes(benefit)	($0.3)	$0.0	$0.0	$0.7	$0.4	($0.7)	$0.0	$0.0	$0.0	($0.7)	$0.0	$0.0
Tax Rate	-	-	-	-	-	-	-	-	-	-	-	-
Reported Net Income	**($3.9)**	**($2.6)**	**($3.1)**	**($3.2)**	**($12.8)**	**($5.9)**	**($5.5)**	**($1.8)**	**($5.0)**	**($18.1)**	**($18.5)**	**($15.0)**
YOY Growth	-	-	-	-	-	-	-	-	-	-	-	-
Net Margin	-	-	-	-	-	-	-	-	-	-	-	-
Shares Out	*2.1*	*2.3*	*2.8*	*3.1*	*2.6*	*3.6*	*4.2*	*4.8*	*11.5*	*6.0*	*15.0*	*20.0*
Reported EPS	**($1.87)**	**($1.13)**	**($1.12)**	**($1.03)**	**($5.00)**	**($1.65)**	**($1.29)**	**($0.37)**	**($0.43)**	**($3.01)**	**($1.23)**	**($0.75)**
YOY Growth	-	-	-	-	-	-	-	-	-	-	-	-
One time charge	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$0.00*	*$4.02*	*$0.00*	*$0.00*	*$0.00*	*$4.02*	*$0.00*	*$0.00*
Non GAAP Net Income	**($3.9)**	**($2.6)**	**($3.1)**	**($3.2)**	**($12.8)**	**($1.9)**	**($5.5)**	**($1.8)**	**($5.0)**	**($14.1)**	**($18.5)**	**($15.0)**
Non GAAP EPS	**($1.87)**	**($1.13)**	**($1.12)**	**($1.03)**	**($5.00)**	**($0.52)**	**($1.29)**	**($0.37)**	**($0.43)**	**($2.34)**	**($1.23)**	**($0.75)**

Source: Company filing and Zacks Investment Research estimates

© Copyright 2013, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Investment Research ("ZIR"), Zacks & Company (ZCO") and Zacks Small-Cap Research ("Zacks SCR") and the issuers covered by the Zacks SCR analysts in the Small-Cap Universe.

ZIR or Zacks SCR Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for non-investment banking services. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.

ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by Zacks SCR. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management.

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned.

ZCO and Zacks SCR are separate legal entities. ZCO is U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corp. This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments through ZCO.

Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in

© Copyright 2013, Zacks Investment Research. All Rights Reserved.

line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution of Zacks Ratings is as follows on the 1039 companies covered: Buy/Outperform- 15.8%, Hold/Neutral- 77.6%, Sell/Underperform – 6.0%. Data is as of midnight on the business day immediately prior to this publication.